Status:
RECRUITING
A Population-based, Multicenter Cohort Study of Combined Screening for Gastrointestinal Tumors
Lead Sponsor:
Xijing Hospital
Conditions:
Digestive Disease
Eligibility:
All Genders
45-70 years
Brief Summary
To establish combined gastroenteroscopy screening and follow-up management for gastrointestinal tumors, explore and evaluate the feasibility and health economic benefits of combined screening for esop...
Detailed Description
group one: The screening population will undergo gastroscopy, colonoscopy, fecal occult blood test (FIT), Helicobacter pylori (HP) antigen test, ring finger protein 180 (RNF180) and SEPTIN9 gene methy...
Eligibility Criteria
Inclusion
- 1\. Subjects were 45 to 70 years old when enrolled 2. Willing and able to sign informed consent
Exclusion
- 1\. History of any type of malignancy 2. Previous resection of esophagus, stomach or colorectal 3. Received gastrointestinal endoscopy such as colonoscopy and gastroscopy in recent 5 years 4. Have received fecal occult blood test and fecal DNA test in the past 1 year. 5. Contraindications to endoscopy. 6. Warning symptoms of digestive tract tumors, including:
- Difficulty swallowing, choking or halting feeling when eating recently
- Recent esophageal foreign body sensation or swallowing pain
- Recent long-term loss of appetite and appetite
- Recent and prolonged symptoms of indigestion (including acid reflux, heartburn, abdominal grumbling, burping, nausea or premature satiety, etc.)
- Recent symptoms of abdominal mass, abdominal pain, vomiting or hematemesis
- It was medically diagnosed as iron deficiency anemia
- Recent changes in hematochezia, black stool or stool character and frequency
- Recent symptoms of perianal discomfort (including soreness, itching, lumps, prolapse or other discomfort)
- Unexplained weight loss (more than 10% of base body weight) in the past 6 months Step 7 Get pregnant 8. There are other serious comorbiditions that reduce screening benefits (including severe lung disease, advanced kidney disease, advanced liver disease, severe heart failure, etc.)
Key Trial Info
Start Date :
August 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2033
Estimated Enrollment :
84000 Patients enrolled
Trial Details
Trial ID
NCT05996458
Start Date
August 1 2023
End Date
June 30 2033
Last Update
October 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gaoyao District People's Hospital
Zhaoqing, Guangzhou, China, 526040